Clinical Trial Update: A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating paclitaxel/carboplatin with or without olaratumab (IMC-3G3) in previously untreated locally advanced or metastatic non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Olaratumab (olaratumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-01-16